Long-term open-label extension study of subcutaneous efgartigimod in adults with chronic inflammatory demyelinating polyneuropathy

Phase 2, open-label, single-arm trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events and Incidence of clinically significant laboratory abnormalities. Started Nov 2021; status: recruiting.